BHC vs. ARVN, INDV, RYTM, JANX, MLTX, ACAD, TGTX, MRUS, DCPH, and GERN
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include Arvinas (ARVN), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), TG Therapeutics (TGTX), Merus (MRUS), Deciphera Pharmaceuticals (DCPH), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
Bausch Health Companies has a net margin of -5.07% compared to Bausch Health Companies' net margin of -185.09%. Bausch Health Companies' return on equity of -64.79% beat Arvinas' return on equity.
In the previous week, Bausch Health Companies had 4 more articles in the media than Arvinas. MarketBeat recorded 10 mentions for Bausch Health Companies and 6 mentions for Arvinas. Bausch Health Companies' average media sentiment score of 1.07 beat Arvinas' score of -0.10 indicating that Arvinas is being referred to more favorably in the media.
Arvinas has higher earnings, but lower revenue than Bausch Health Companies. Arvinas is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Arvinas has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
95.2% of Arvinas shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 8.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Arvinas currently has a consensus price target of $61.13, suggesting a potential upside of 84.80%. Bausch Health Companies has a consensus price target of $11.33, suggesting a potential upside of 78.48%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities analysts plainly believe Arvinas is more favorable than Bausch Health Companies.
Bausch Health Companies received 179 more outperform votes than Arvinas when rated by MarketBeat users. However, 65.40% of users gave Arvinas an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
Summary
Arvinas beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch Health Companies Competitors List
Related Companies and Tools
